


Figure: Patients selection



¹ Established on a median of 17 (IQR:11-25) CD4 measurements

² Established on a median of 14 (IQR:9-20) pVL measurements

³ The CD4 slope over the last 5 years is evaluate on at least 3 measurements of CD4 in the last 5 years before 2005 among which at least 1 measurement of more than 4 years.

Table : Description of different groups of patients characterized in 2005 in the FHDH and who were asymptomatic and therapy naïve.

| | HIV infection ≥8 years | | | HIV infection >10 years | |
|---|------------------------|---|--|---|--|
| | N=903 patients | LTNP pts CD4 cells count nadir ≥500/mm ³ N=202 patients | Elite LTNP pts CD4 cells count nadir ≥600 and CD4 slope ≥ 0 N=25 patients | HIV controller with 90% of pVL measurements ≤ 500 copies/mL. N=101 patients | Elite controller with 90% of pVL measurements ≤ 500 copies/mL and the last pVL ≤50 copies/mL N=69 patients |
| Sex n(%) | | | | | |
| Women | 323 (35.8) | 68 (33.7) | 7 (28.0) | 40 (39.6) | 26 (37.7) |
| Men | 580 (64.2) | 134 (66.3) | 18 (72.0) | 61 (60.4) | 43 (62.3) |
| Transmission group n(%) | | | | | |
| Homosexual | 281 (31.1) | 77 (38.1) | 11(44.0) | 11 (10.9) | 8 (11.6) |
| IVDU | 231 (25.6) | 47 (23.3) | 6 (24.0) | 42 (41.6) | 30 (43.5) |
| Heterosexual | 303 (33.6) | 62 (30.7) | 6 (24.0) | 31 (30.7) | 19 (27.5) |
| Transfusion | 32 (3.5) | 5 (2.5) | 1 (4.0) | 11 (10.9) | 8 (12.6) |
| Others | 56 (6.2) | 11 (5.4) | 1 (4.0) | 6 (5.9) | 4 (5.8) |
| Geographic Origin n(%) | | | | | |
| France | 791 (87.6) | 181 (89.6) | 23 (92.0) | 92 (91.1) | 64 (92.8) |
| Sub-Saharan Africa | 48 (5.3) | 10 (5.0) | 0 (0.0) | 7 (6.9) | 4 (5.8) |
| Other | 64 (7.1) | 11 (5.4) | 2 (8.0) | 2 (2.0) | 1 (1.4) |
| CD4 cell count nadir until end of 2005 (/mm³) | 356 (279-479) | 600 (549-686) | 670 (632-722) | 450 (288-632) | 484 (296-671) |
| Maximum pVL (copies/ml) until end of 2005 | 20100 (3560-68814) | 7280 (800-32472) | 1970 (500-13000) | 500 (500-500) | 500 (500-500) |
| At HIV diagnosis | | | | | |
| Age Median (IQR) | 28.2 (23.9-33.9) | 28.6 (24.7-33.9) | 27.8 (24.2-30.5) | 27.9 (24.4-35.3) | 27.9 (24.4-35.6) |
| Year of HIV diagnosis median (IQR) | 1992 (1988-1995) | 1992 (1989-1995) | 1991 (1988-1994) | 1990 (1986-1993) | 1990 (1987-1994) |
| At FHDH enrolment | | | | | |
| Age Median (IQR) | 32.9 (28.2-38.8) | 33.9 (28.8-38.7) | 34.8 (29.0-36.7) | 34.2 (29.2-41.1) | 34.9 (29.6-41.7) |
| CD4 cell count (/mm³) Median (IQR) | 632 (483-827) | 858 (717-1070) | 852 (738-975) | 729 (539-926) | 740 (524-939) |
| pVL (copies/ml) | | | | | |
| Missing n(%) | 379 (42.0) | 99 (49.0) | 11 (44.0) | 67 (66.6) | 43 (62.3) |
| Median (IQR) | 2609 (500-10000) | 7961 (500-4500) | 665 (500-10000) | 500 (68-500) | 500 (50-500) |
| In 2005 (last follow-up visit) | | | | | |
| Age Median (IQR) | 42.9 (38.5-47.5) | 42.5 (39.2-47.5) | 42.2 (39.8-45.3) | 44.5 (41.0-50.0) | 44.5 (40.9-48.5) |
| CD4 cell count (/mm³) Median (IQR) | 473 (359-634) | 759 (635-912) | 946 (871-946) | 661 (490-888) | 721 (495-912) |
| pVL (copies/ml) Median (IQR) | 5872 (646-28700) | 2149 (132-15900) | 168 (50-5868) | 50 (50-139) | 50 (50-50) |
| ≤ 50 copies/ml n(%) | 106 (11.7) | 45 (22.3) | 10 (40.0) | 69 (68.3) | 69 (100.0) |
| ≤ 500 copies/ml n(%) | 210 (23.2) | 76 (37.6) | 14 (56.0) | 99 (98.0) | 69 (100.0) |

Table (continued)

| | HIV infection ≥8 years | | | HIV infection >10 years | |
|---|------------------------|---|--|---|--|
| | N=903 patients | LTNP pts CD4 cells count nadir ≥500/mm ³ N=202 patients | Elite LTNP pts CD4 cells count nadir ≥600 and CD4 slope ≥ 0 N=25 patients | HIV controller with 90% of pVL measurements ≤ 500 copies/mL. N=101 patients | Elite controller with 90% of pVL measurements ≤ 500 copies/mL and the last pVL ≤50 copies/mL N=69 patients |
| CD8 cell count (/mm³) | | | | | |
| Missing n(%) | 222 (24.6) | 55 (27.3) | 7 (28.0) | 29 (28.7) | 18 (26.1) |
| Median (IQR) | 970 (697-1345) | 1045 (747-1560) | 1091 (888-1275) | 808 (630-1250) | 817 (562-1119) |
| CD4/CD8 Median (IQR) | 0.5 (0.3-0.7) | 0.8 (0.5-1.1) | 0.9 (0.8-1.2) | 0.9 (0.6 –1.3) | 0.9 (0.7-1.4) |
| CD4/CD8 ≥1 n(% among pts with available CD8) | 78 (11.5) | 44 (29.9) | 8 (44.4) | 29 (40.3) | 24 (47.1) |

Note: IVDU : Intra-venous drug user. IQR : inter-quartile range. LTNP : long-term non progressor. pVL : Plasma viral load.

Additional Figure Overlap among the 4 groups of patients with slow disease progression in the FHDH.

Note: The number indicates the number of patient in each group.

